Lupin Slumps To Q4 Loss Amid US Opioid Action But Build Up In Inhalation, Biosimilars

 
• By Anju Ghangurde
Cubes
LUPIN HAS BEEN FACING HEADWINDS IN THE US

More from Business

More from Scrip